Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Hoffmann-La Roche
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Atara Biotherapeutics
Genelux Corporation
AVEO Pharmaceuticals, Inc.